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Abstract
Background: Estimates suggest that only 20 % of HCV-infected patients have been identified and <10 % treated.
However, baby boomers (1945-1965) are identified as having a higher prevalence of HCV which has led the Centers
for Disease Control and Prevention to make screening recommendations. The aim of this study was to implement
the CDC’s screening recommendations in the unique setting of gastroenterology practices in patients previously
unscreened for HCV.
Methods: After obtaining patient informed consent, demographics, clinical and health-related quality of life
(HRQOL) data were collected. A blood sample was screened for HCV antibody (HCV AB) using the OraQuick HCV
Rapid Antibody Test. HCV AB-positive patients were tested for presence of HCV RNA and, if HCV RNA positive,
patients underwent treatment discussions.
Results: We screened 2,000 individuals in 5 gastroenterology centers located close to large metropolitan areas on
the East Coast (3 Northeast, 1 Mid-Atlantic and 1 Southeast). Of the screened population, 10 individuals (0.5 %)
were HCV AB-positive. HCV RNA testing was performed in 90 % (9/10) of HCV AB-positive individuals. Of those,
44.4 % (4/9) were HCV RNA-positive, and all 4 (100 %) were linked to caregiver. Compared to HCV AB negative
subjects, HCV AB-positive individuals tended to be black (20.0 vs. 5.2 %, p = 0.09) and reported significantly higher
rates of depression: 60.0 vs. 21.5 %, p = 0.009. These individuals also reported a significantly lower HRQOL citing
having more fatigue, poorer concentration, and a decreased level of energy (p < 0.05).
Discussion: Although the prevalence of HCV AB-positive was low in previously unscreened subjects screened in
the gastroenterology centers, the linkage to care was very high. The sample of patients used in this study may be
biased, so further studies are needed to assess the effectiveness of the CDC screening recommendations.
Conclusion: Implementation of the Baby Boomer Screening for HCV requires identifying screening environement
with high prevalence of HCV+ individuals as well as an efficient process of linking them to care.
Background
Hepatitis C viral (HCV) infection is the leading cause of
cirrhosis and hepatocellular carcinoma in the United
States, and the most common indication for liver trans-
plantation [1–4]. There is increasing evidence that HCV
is a systemic disease with both hepatic and extrahepatic
manifestations [1]. There is also significant evidence that
HCV infection is associated with tremendous economic
burden including both direct and indirect costs associ-
ated with management of HCV-related hepatic and ex-
trahepatic manifestations as well as lost years of life,
impaired quality of life and work productivity [1–9] On
the other hand, sustained viral response (SVR) of HCV
infection has been reported to improve morbidity and
mortality as well as health-related quality of life and
work productivity in patients with HCV [10–13]. With
the current all-oral second generation direct-acting anti-
viral agents, over 95 % of treated patients can achieve
SVR with an excellent safety profile [14–29].
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Despite substantial gains in treating HCV with these
new highly effective antiviral regimens, there are a number
of barriers which still exist [30–34]. Of these, the two
most notable barriers are difficulty in obtaining insurance
funding for the new regimens and the identification of all
HCV infected patients [30–34]. The current estimates
suggest that only between 10–50 % of HCV infected pa-
tients in the US are currently diagnosed [31]. This is partly
due to health care providers’ lack of enthusiasm about the
previous anti-HCV treatment regimens and their substan-
tial side effect profile. Additionally, the recommended
risk-based screening has not been effective in identifying
infected patients [35]. Since 1998, the CDC has sug-
gested HCV antibody screening of individuals with past
behaviors or health indicators associated with HCV in-
fection (e.g., history of injection drug use, hemodialysis, etc.).
Despite these recommendations, more than 50 % of indi-
viduals with chronic hepatitis C (CHC) continue to be un-
aware of their infections, leading to questions about the
effectiveness of such “risk-based” screening [36, 37].
In the United States, HCV infection is most prevalent
among individuals born between 1945 and 1965
accounting for approximately 75 % of hepatitis C-
associated mortality [38]. Since more than 50 % of
infected individuals are unaware of their infection, the
number of adults with CHC that will progress to cirrho-
sis, liver failure, hepatocellular carcinoma, and death is
expected to increase dramatically in the coming decades
[38, 39]. Without changes to CH-C screening, diagnos-
ing and treatment paradigms, over the next 20 years, the
total medical costs for individuals with HCV infection
are expected to more than double, from $30 billion to
over $85 billion [40]. Therefore, in 2012, CDC adjusted
their recommendations to include a one-time hepatitis C
screening of all individuals born between 1945 and 1965
[41]. The US Preventive Services Task Force has stepped
forward and supported the CDC’s recommendation for
birth cohort screening as well [42].
With therapies achieving SVR in >90 % of patients,
targeted testing and link to care for infected persons in
this birth cohort are expected to reduce HCV-related
morbidity and mortality [35]. Therefore, the aim of this
study was to implement a pilot screening project in 5
real world Gastroenterology Practices to identify baby
boomers infected with HCV and to test the feasibility of




This is a multi-center study sponsored by Chronic Liver
Disease Foundation that involved 5 gastroenterology prac-
tices selected by the American College of Gastroenterology.
The sites were large clinical practices within metropolitan
areas that had familiarity with standard preventative screen-
ing procedures (e.g., colon cancer screening) and Good
Clinical Practices (i.e., informed consent, data privacy, data
collection). Enrollment started in 2014 and was completed
in June 2015; it was competitive and not capped at any
given site. Inclusion criteria were as follows: male and
female patients born between 1945 and 1965, inclusive;
willingness to give written informed consent; ability to read
and understand English. Patients with documented history
of HCV antibody (HCV Ab) or HCV RNA screening were
excluded. To obtain baseline information, all patients were
asked to fill out two questionnaires - one with their demo-
graphic and basic clinical history and one with health-
related quality of life information (HRQL). Each patient
underwent a blood draw to obtain a sample of blood for
HCV screening. If the patient tested positive for HCVAb, a
standard of care confirmatory test was performed.
Clinical and HRQL data
After informed consent, demographic, clinical and qual-
ity of life data were obtained. In particular, all enrolled
individuals reported their age, gender, race/ethnicity and
zip code. Medical history questionnaire asked about
history of diabetes mellitus, hypertension, hyperlipidemia
(that or high cholesterol or high triglycerides), heart
disease (not specified), and about experiencing anxiety,
depression, and fatigue. Individuals were also asked
about recent alcohol consumption (3 or more drinks a
week for a year) and about their current smoking status.
To assess fatigue, vitality, and exertion, 20 items from
three widely used and extensively validated HRQL assess-
ment instruments were selected and included into one
questionnaire [43–47]. Specifically, the items were chosen
from the physical functioning domain (PF) of the SF-36,
the activity/energy (AE) and emotional (EM) domains of
CLDQ-HCV, and the fatigue scale domain (FS) of FACIT-
F [43–47]. The questionnaire was in English and self-
administered. The responses to individual items were col-
lected and, after transformation to a universal scale, were
averaged to a total generic HRQL score (0–100).
Screening for HCV infection
Sites were provided with commercially approved OraQuick
HCV Rapid Antibody Test kits (OraSure Technologies).
Each subject’s blood sample was screened for HCV Ab
using Oraquick anti-HCV test. An adverse event was de-
fined as any medical occurrence in response to the admin-
istration of the OraQuick Rapid HCV Test.
Individuals who were HCV Ab-negative were no longer
followed-up for this study. For HCV Ab-positive individ-
uals, a standard of care confirmatory testing was ordered
by the screening site (as per standard medical practice)
such as HCV RNA test, and results were collected. Indi-
viduals were also counseled and educated on HCV,
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including the use of alcohol, acetaminophen, and receiving
hepatitis A and B vaccinations. The HCVAb-positive indi-
viduals who consented to be followed also completed a
four week follow-up HRQL survey. Finally, HCV RNA
positive individuals were linked to care within the site
practice or the geographical area and the date of the
scheduled visit was recorded. The site also followed
instructions regarding the local state requirements on
whether a positive result had to be reported to a state
health department.
The study outcomes and statistical analysis
The primary endpoint of this study was the percentage
of individuals with a positive HCV Ab. The secondary
endpoints were the percentages of HCV Ab-positive
individuals who underwent confirmatory testing and
were linked to care, and HRQL scores at baseline and at
follow-up.
The demographic and clinical parameters of individ-
uals who were HCV Ab-positive or HCV Ab-negative
were compared using Fisher exact test or Mann-
Whitney non-parametric test. Individual HRQL items
were treated as ordinal parameters; the total HRQL
score was considered continuous. A p-value of less than
0.05 was considered significant. Independent predictors
of a positive HCV Ab result were evaluated by a logistic
regression using all collected clinico-demographic pa-
rameters as predictors. All analyses were run in SAS 9.3
(SAS Institute, Cary, NC). The study was approved by
Copernicus IRB Board.
Results
Two thousand baby boomer individuals were con-
sented and screened in 5 gastroenterology practices
selected by American College of Gastroenterology
(regions: 3 Northeast, 1 Mid-Atlantic and 1 Southeast).
The demographic and clinical data is summarized in
Table 1, and HRQL data is summarized in Table 2.
Screened individuals were, on average, 60 ± 6 years
old, 40 % male, 72 % Caucasian, 21 % Hispanic and 5 %
African-American. Also, 30 % reported history of anx-
iety, 22 % reported depression and 38 % reported clinic-
ally overt fatigue. Furthermore, 16 % had a history of
diabetes, 43 % had a history of hypertension, and 48 %
had history of hyperlipidemia. Additionally, 27.5 % re-
ported drinking alcohol ≥3 drinks per week, and 10.2 %
reported current smoking (Table 1).
Of the screened population, 10 individuals (0.5 %) had
positive serology for HCV. Of those, 4 (40 %) reported
history of IV drug use and 2 (20 %) a history of intrana-
sal drug use, 4 (40 %) had an unregulated tattoo, 1
(10 %) had a history of incarceration, and 1 (10 %) re-
ported a history of blood transfusion before 1992
(Table 3).
The HCV RNA testing was done in 90 % (9/10) of
HCV-antibody positive individuals, and 44.4 % (4/9)
Table 1 Demographics and medical history of the screened birth cohort
HCV Ab+ HCV Ab- p All subjects
N 10 1,990 2,000
Age, years 58.4 ± 3.2 59.8 ± 6.0 0.41 59.8 ± 6.0
Race or ethnicity
Caucasian 8 (80.0 %) 1429 (71.8 %) 0.73 1437 (71.9 %)
African-American 2 (20.0 %) 103 (5.2 %) 0.0933 105 (5.3 %)
Hispanic 0 (0.0 %) 418 (21.0 %) 0.13 418 (20.9 %)
Asian 0 (0.0 %) 26 (1.3 %) 1.00 26 (1.3 %)
Other 0 (0.0 %) 14 (0.7 %) 1.00 14 (0.7 %)
Male gender 4 (40.0 %) 793 (39.8 %) 1.00 797 (39.9 %)
History of:
Type 2 diabetes 3 (30.0 %) 308 (15.5 %) 0.20 311 (15.6 %)
Hypertension 5 (50.0 %) 858 (43.4 %) 0.75 863 (43.4 %)
Hyperlipidemia 4 (40.0 %) 951 (47.9 %) 0.76 955 (47.8 %)
Anxiety 4 (40.0 %) 600 (30.3 %) 0.50 604 (30.3 %)
Depression 6 (60.0 %) 424 (21.5 %) 0.0094 430 (21.7 %)
Fatigue 6 (60.0 %) 742 (37.5 %) 0.19 748 (37.6 %)
Heart disease 2 (20.0 %) 219 (11.1 %) 0.31 221 (11.1 %)
Alcohol consumption > 30 g/week 3 (30.0 %) 545 (27.5 %) 1.00 548 (27.5 %)
Current smoking 3 (30.0 %) 199 (10.1 %) 0.0731 202 (10.2 %)
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were found to be HCV RNA-positive, 100 % of whom were
counseled and linked to care by establishing an appointment
regarding their HCV. Compared to HCV-antibody negative
individuals, those who were HCV-antibody positive tended
to be African-Americans (20.0 vs. 5.2 %, p= 0.09) and re-
port more frequently a history of depression: 60.0 vs.
21.5 % (p = 0.009) (Table 1). Multivariate analysis with
logistic regression showed that depression was the
only clinical parameter independently associated with
being HCV-antibody positive [odds ratio (95 % confi-
dence interval) = 5.49 (1.54–19.54)].
The HCV-antibody positive individuals also had lower
quality of life as documented by more fatigue, poorer
concentration, less activity, and decreased levels of
energy (all p-values < 0.05) (Table 2). The four weeks
follow-up HRQOL questionnaire showed no significant
changes (all p > 0.1) from the baseline values in individ-
uals who tested positive for HCV (Table 4).
Discussion
This is the largest HCV screening program in the baby
boomers who presented to a specialty gastroenterology
practices for clinical care. The data suggest that the
prevalence of HCV antibody positivity in this particular
study setting (subjects visiting GE practices who have
not previously been identified) is relatively low (0.5 %) as
compared to the reported HCV AB positive rate in the
general population at 4.1 % for males and 1.6 % for
females [48]. It is important to note that, in addition to
a bias introduced solely by the fact of patients being seen
Table 2 Quality of life in the screened birth cohort
Question text Range a Instrument, item (domain) HCV Ab




How much have you been tired or fatigued
during the last 2 weeks?
1–7 CLDQ-HCV Q1 (AE) 3.60 ± 1.96 4.82 ± 1.70 0.0412 4.82 ± 1.70
How much difficulty have you had with
bending, lifting, or stooping in the last 2 weeks?
1–7 CLDQ-HCV Q4 (AE) 5.10 ± 1.85 5.53 ± 1.69 0.37 5.53 ± 1.69
How often during the last 2 weeks have you
felt a decreased level of energy?
1–7 CLDQ-HCV Q7 (AE) 3.80 ± 2.10 4.98 ± 1.69 0.0155 4.97 ± 1.69
How often during the last 2 weeks have you
felt depressed?
1–7 CLDQ-HCV Q16 (EM) 4.40 ± 2.12 5.88 ± 1.49 0.0144 5.87 ± 1.50
How much of the time during the last 2 weeks
have you had problems concentrating?
1–7 CLDQ-HCV Q18 (AE) 4.80 ± 1.75 5.70 ± 1.47 0.0471 5.70 ± 1.47
The following questions are about activities you
might do during a typical day. Does your health
now limit you in these activities? If so, how much?
Vigorous activities, such as running, lifting heavy
objects, participating in strenuous sports
1–3 SF-36 PF01 2.10 ± 0.99 2.13 ± 0.82 0.41 2.13 ± 0.82
Moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling, or playing golf
1–3 SF-36 PF02 2.20 ± 1.03 2.60 ± 0.67 0.0122 2.59 ± 0.67
Lifting or carrying groceries 1–3 SF-36 PF03 2.30 ± 0.95 2.67 ± 0.60 0.0450 2.67 ± 0.60
Climbing several flights of stairs 1–3 SF-36 PF04 2.20 ± 0.92 2.47 ± 0.72 0.29 2.47 ± 0.72
Climbing one flight of stairs 1–3 SF-36 PF05 2.20 ± 1.03 2.69 ± 0.60 0.0064 2.68 ± 0.61
Bending, kneeling, or stooping 1–3 SF-36 PF06 2.40 ± 0.84 2.47 ± 0.70 0.65 2.47 ± 0.70
Walking more than a mile 1–3 SF-36 PF07 2.20 ± 0.79 2.46 ± 0.76 0.22 2.46 ± 0.76
Walking several hundred yards 1–3 SF-36 PF08 2.10 ± 0.88 2.66 ± 0.64 0.0195 2.66 ± 0.64
Walking one hundred yards 1–3 SF-36 PF09 2.10 ± 0.99 2.73 ± 0.58 0.0063 2.72 ± 0.59
Bathing or dressing yourself 1–3 SF-36 PF10 2.60 ± 0.84 2.86 ± 0.44 0.10 2.86 ± 0.44
Please indicate how true each statement has
been for you during the past 7 days.
I feel fatigued 4–0 FACIT-F HI7 (FS) 2.10 ± 1.45 1.11 ± 1.20 0.0107 1.11 ± 1.20
I feel tired 4–0 FACIT-F An2 (FS) 2.00 ± 1.49 1.25 ± 1.16 0.15 1.25 ± 1.16
I have trouble starting things because I am tired 4–0 FACIT-F An3 (FS) 1.70 ± 1.64 0.80 ± 1.12 0.0148 0.80 ± 1.13
I have energy 0–4 FACIT-F An5 (FS) 1.80 ± 0.63 2.41 ± 1.18 0.0352 2.41 ± 1.18
I need help doing my usual activities 4–0 FACIT-F An14 (FS) 0.80 ± 0.79 0.37 ± 0.86 0.0100 0.37 ± 0.86
Average score 0–100 generic 58.9 ± 32.5 76.3 ± 21.3 0.071 76.2 ± 21.4
a the range is from the worst to the best health status. Higher scores indicate better HRQOL
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in tertiary care centers in a small sample of localities,
our study excluded individuals who had already been
diagnosed with HCV or had been screened for HCV
previously due to meeting certain high risk criteria.
Therefore, the prevalence rate reported in this study is
likely substantially lower than one that could have been
obtained in a community-based screening setting, and
neither does it reflect the true HCV prevalence in the
GE practices (due to exclusion of those with an existing
diagnosis of HCV).
Our study also indicates that about half of the individ-
uals who were HCV antibody positive were viremic. In
this HCV cohort, risk factors reported were similar to
those previously known for HCV viremic patients [1–4].
Furthermore, African Americans tended to have a higher
prevalence of HCV which is also consistent with previous
reports. Additionally, those testing HCV positive had
more depression independently associated with their
HCV positivity status. All HCV positive individuals were
linked to follow-up care through scheduled appointments.
This is a significant finding as this part of the screening,
diagnosis, and treatment continuum has been a challenge
in other settings such as emergency rooms [2].
These data are similar to those reported by Sears et al.
from a single GE practice for baby boomers undergoing
colonoscopy. In fact, in that study, only one of 376
subjects (0.27 %) was HCV RNA positive, a rate almost
identical to our HCV viremic individuals (0.2 %) [3].
There are a number of potential explanations for the
relatively low prevalence of HCV in GE practices. The
most important explanation may be related to the type
of patients who are seen in GE practices – they are most
likely insured with the majority (72 %) being Caucasians.
The low prevalence of HCV in this special population
as compared to a community-based approach is of spe-
cial importance as specialty practices may not be the
best places to screen for HCV but may provide the best
avenue for follow-up care once identified. For instance,
Galbraith et al. reported screening of baby boomers in
an emergency room. These authors reported an 11.1 %
positive HCV antibody rate with 68 % being viremic. On
the other hand, only 54 % of HCV viremic patients were
able to be contacted and 38 % were able to be scheduled
for follow-up appointments indicating a significant
drop-off [2].
In addition to high prevalence of HCV in the baby
boomers seen in the emergency department, the preva-
lence rates are also high for baby boomers screened in
the hospital setting. In a study by Turner et al., the
prevalence of newly diagnosed HCV in hospitalized baby
boomers was 8 % [4]. Finally, in a study reported by
Morano et al., baby boomers were screened either by
point of care (POC) HCV antibody testing or traditional
serologic testing in the setting of a mobile medical clinic.
The reported prevalence of HCV positivity in this cohort
was 6.2 %. Individuals who underwent POC testing were
much more likely (93.8 %) than traditional serologic test-
ing (18.2 %) to be linked to care [5]. In a recent model-
ing study from 15 countries worldwide, investigators
found that diagnosing and treating a small proportion of
patients with high efficacy drugs can have a significant
effect on the reduction of the HCV disease burden
within the countries studied [49]. At the same time, the
authors caution that the best scenario would be to have
increased diagnosis and treatment with high efficacy
treatments to have the best results. Others, though,
argue that the model used was not a dynamic model and
thus may not capture any new infection or reinfections
so may overestimate the true impact of the use of high
efficacy drugs [50].
These findings not only assist healthcare workers in
identifying better areas for the identification of HCV but
may assist healthcare workers in providing a better
method to link screening with follow-up care. Link to
care is important to deliver the highly effective antiviral
treatment to patients with HCV. Our data suggest high
rates of linking to care for patients who are HCV-
positive to a GE clinic. Nevertheless, given the small
sample size, the generalizability of this data must be
interpreted with caution. Furthermore, if a GE clinic is
Table 3 Additional socio-demographic information and link to
care for HCV Ab + patients (N = 10)
N (%) or mean ± std.dev.
Confirmed HCV ab+ 10 (100.0 %)
HCV RNA-positive a 4 (44.4 %)
ALT, IU/mL 32.8 ± 35.4
AST, IU/mL 25.2 ± 21.7
History of:
Past or current IV drug use 4 (40.0 %)
Blood transfusions before 1992 1 (10.0 %)
Long-term hemodialysis 0 (0.0 %)
Incarceration 1 (10.0 %)
Being born to HCV-infected
mother
0 (0.0 %)
Intranasal drug use 2 (20.0 %)




Acetaminophen use 9 (90.0 %)
Alcohol consumption 10 (100.0 %)
Hepatitis A and B vaccination 9 (90.0 %)
Linked to care 9 (90.0 %)
Completed follow-up questionnaire 6 (60 %)
aone HCV ab + patient refused to give blood sample
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not available another suggested method is the use of
Innovative Mobile Clinics equipped with POC testing
for HCV that use established pathways [5]. Using mobile
clinics allow for HCV-positive patients to be immedi-
ately linked to care.
In this study, we also assessed the quality of life in all
patients at baseline before they knew their HCV infec-
tion status as there are previous data which suggest that
knowledge about HCV diagnosis can impair HRQL [51].
We have found that at baseline patients who were HCV
AB+ had more impairment of their HRQL having more
complaints of fatigue, poorer concentration, less activity,
and decreased levels of energy as compared to those
who were HCV AB-. This is consistent with previous
data which have demonstrated that HCV-infected pa-
tients suffer from HRQL impairment possibly due to the
potential effects of the virus crossing the blood-brain bar-
rier and affecting the brain chemistry directly [52–54]. In
our study, for the patients who were HCV AB+, a follow-
up survey was administered 4 weeks after their initial
diagnosis, and there were no statistically significant
change in their reported HRQL indicating that knowing
the status of being HCV AB+ did not influence their
HRQL. However, the small sample size of our study may
have contributed to our inability to detect this difference
in the HRQOL scores.
One of the limitation of this study was the study popula-
tion referred to a GE practice indicating access to insur-
ance coverage for consultative services and colonoscopy.
This could potentially introduce a bias by excluding unin-
sured individuals who are known to have high prevalence
of HCV (30). Another limitation of our study was our
Table 4 Follow-up HRQL questionnaire in HCV Ab + patients (N = 6)
Question text Range a Instrument, item (domain) baseline 4 week f/u
How much have you been tired or fatigued
during the last 2 weeks?
1–7 CLDQ-HCV, Q1 (AE) 4.00 ± 1.26 4.50 ± 1.64
How much difficulty have you had with bending,
lifting, or stooping in the last 2 weeks?
1–7 CLDQ-HCV, Q4 (AE) 5.17 ± 1.83 5.33 ± 1.37
How often during the last 2 weeks have you felt
a decreased level of energy?
1–7 CLDQ-HCV, Q7 (AE) 4.00 ± 1.55 4.50 ± 1.64
How often during the last 2 weeks have you felt
depressed?
1–7 CLDQ-HCV, Q16 (EM) 5.17 ± 1.94 5.00 ± 1.55
How much of the time during the last 2 weeks
have you had problems concentrating?
1–7 CLDQ-HCV, Q18 (AE) 5.17 ± 1.17 5.50 ± 1.05
The following questions are about activities you might
do during a typical day. Does your health now limit
you in these activities? If so, how much?
Vigorous activities, such as running, lifting heavy objects,
participating in strenuous sports
1–3 SF-36, PF01 (PF) 2.17 ± 0.98 2.00 ± 0.89
Moderate activities, such as moving a table, pushing a
vacuum cleaner, bowling, or playing golf
1–3 SF-36, PF02 (PF) 2.33 ± 1.03 2.33 ± 0.82
Lifting or carrying groceries 1–3 SF-36, PF03 (PF) 2.50 ± 0.84 2.33 ± 0.82
Climbing several flights of stairs 1–3 SF-36, PF04 (PF) 2.33 ± 0.82 2.17 ± 0.98
Climbing one flight of stairs 1–3 SF-36, PF05 (PF) 2.33 ± 1.03 2.17 ± 0.98
Bending, kneeling, or stooping 1–3 SF-36, PF06 (PF) 2.50 ± 0.84 2.00 ± 0.89
Walking more than a mile 1–3 SF-36, PF07 (PF) 2.17 ± 0.75 2.17 ± 0.98
Walking several hundred yards 1–3 SF-36, PF08 (PF) 2.00 ± 0.89 2.33 ± 0.82
Walking one hundred yards 1–3 SF-36, PF09 (PF) 2.00 ± 1.10 2.33 ± 0.82
Bathing or dressing yourself 1–3 SF-36, PF10 (PF) 2.67 ± 0.82 2.67 ± 0.82
Please indicate how true each statement has been for
you during the past 7 days.
I feel fatigued 4–0 FACIT-F HI7 (FS) 2.00 ± 1.10 1.33 ± 1.51
I feel tired 4–0 FACIT-F An2 (FS) 2.00 ± 1.41 1.50 ± 1.38
I have trouble starting things because I am tired 4–0 FACIT-F An3 (FS) 1.33 ± 1.37 1.33 ± 1.21
I have energy 0–4 FACIT-F An5 (FS) 2.00 ± 0.63 1.67 ± 0.52
I need help doing my usual activities 4–0 FACIT-F An14 (FS) 0.50 ± 0.55 1.00 ± 0.89
Average score 0–100 Generic 63.1 ± 29.9 63.4 ± 27.9
athe range is from the worst to the best health status
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focus on “the age cohort” as the risk factor for HCV.
Although this was done to determine the prevalence of
HCV solely based on the age-based risk factor, other risks
were not included.
Conclusions
In summary, our data show that the outcome of screening
and then linkage to care for the baby boomers found to be
HCV-positive is feasible but may depend on the setting. In
this study, GE practices appeared to have a low prevalence
of HCV, but the linkage to care occurred universally.
Therefore, a strategy to maximize both the yield of HCV
screening and linkage to care with appropriate providers
will be critical for identifying and successfully treating
patients infected with HCV.
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